Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study.
Miglietta F, Collesei A, Vernieri C, Giarratano T, Giorgi CA, Girardi F, Griguolo G, Cacciatore M, Botticelli A, Vingiani A, Fotia G, Piacentini F, Massa D, Zanghì F, Marino M, Pruneri G, Fassan M, Dei Tos AP, Dieci MV, Guarneri V. Miglietta F, et al. Among authors: griguolo g. ESMO Open. 2025 Jan;10(1):104087. doi: 10.1016/j.esmoop.2024.104087. Epub 2024 Dec 19. ESMO Open. 2025. PMID: 39705838 Free PMC article.
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives.
Ferro A, Bottosso M, Dieci MV, Scagliori E, Miglietta F, Aldegheri V, Bonanno L, Caumo F, Guarneri V, Griguolo G, Pasello G. Ferro A, et al. Among authors: griguolo g. Crit Rev Oncol Hematol. 2024 Nov;203:104479. doi: 10.1016/j.critrevonc.2024.104479. Epub 2024 Aug 14. Crit Rev Oncol Hematol. 2024. PMID: 39151838 Free article. Review.
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.
Massa D, Vernieri C, Nicolè L, Criscitiello C, Boissière-Michot F, Guiu S, Bobrie A, Griguolo G, Miglietta F, Vingiani A, Lobefaro R, Taurelli Salimbeni B, Pinato C, Schiavi F, Brich S, Pescia C, Fusco N, Pruneri G, Fassan M, Curigliano G, Guarneri V, Jacot W, Dieci MV. Massa D, et al. Among authors: griguolo g. J Natl Cancer Inst. 2024 Dec 1;116(12):1914-1927. doi: 10.1093/jnci/djae178. J Natl Cancer Inst. 2024. PMID: 39083015 Free PMC article.
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, Fucà G, Lobefaro R, Lalli L, Vingiani A, Nichetti F, Griguolo G, Sirico M, Bernocchi O, Marra A, Corti C, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Presti D, Sposetti C, Giorgi CA, Guarneri V, Pedersini R, Losurdo A, Generali D, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Zattarin E, et al. Among authors: griguolo g. Ther Adv Med Oncol. 2023 Dec 20;15:17588359231204857. doi: 10.1177/17588359231204857. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38130467 Free PMC article.
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data.
Giordano G, Griguolo G, Landriscina M, Meattini I, Carbone F, Leone A, Del Re M, Fogli S, Danesi R, Colamaria A, Dieci MV. Giordano G, et al. Among authors: griguolo g. Crit Rev Oncol Hematol. 2023 Dec;192:104185. doi: 10.1016/j.critrevonc.2023.104185. Epub 2023 Oct 18. Crit Rev Oncol Hematol. 2023. PMID: 37863404 Free article. Review.
The Impact of COVID-19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center in Italy.
Girardi F, Marini S, Porra F, Carpentieri S, Marchet A, Saibene T, Lo Mele M, Giarratano T, Giorgi CA, Mioranza E, Falci C, Faggioni G, Caumo F, Griguolo G, Dieci MV, Guarneri V. Girardi F, et al. Among authors: griguolo g. Oncologist. 2023 Dec 11;28(12):e1179-e1184. doi: 10.1093/oncolo/oyad255. Oncologist. 2023. PMID: 37699107 Free PMC article. Review.
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Dieci MV, Conte P, Bisagni G, Bartolini S, Frassoldati A, Generali D, Piacentini F, Griguolo G, Tagliafico E, Brasó Maristany F, Chic N, Paré L, Miglietta F, Vicini R, D'Amico R, Balduzzi S, Prat A, Guarneri V. Dieci MV, et al. Among authors: griguolo g. J Natl Cancer Inst. 2024 Jan 10;116(1):69-80. doi: 10.1093/jnci/djad179. J Natl Cancer Inst. 2024. PMID: 37676829 Free PMC article.
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Girardi F, Bottosso M, Bisagni A, Zarrilli G, Porra F, Iannaccone D, Dore L, Gaudio M, Santandrea G, Fassan M, Lo Mele M, De Sanctis R, Zambelli A, Bisagni G, Guarneri V, Dieci MV. Miglietta F, et al. Among authors: griguolo g. Clin Cancer Res. 2023 Sep 1;29(17):3429-3437. doi: 10.1158/1078-0432.CCR-23-0480. Clin Cancer Res. 2023. PMID: 37417941 Free PMC article.
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study.
Miglietta F, Carraro V, Amato O, Griguolo G, Bottosso M, Munari G, Zarrilli G, Lo Mele M, Barbieri C, Dei Tos AP, Guarneri V, Dieci MV, Fassan M. Miglietta F, et al. Among authors: griguolo g. J Clin Pathol. 2024 Sep 19;77(10):690-696. doi: 10.1136/jcp-2023-208856. J Clin Pathol. 2024. PMID: 37344170 Free PMC article.
84 results